ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2437

Prevalence Of Axial Spondyloarthritis In The United States Among Patients With Chronic Back Pain and Other Spondyloarthritis-Related Features

Atul A. Deodhar1, Philip J. Mease2, Jeffrey R. Curtis3, Piyalal M. Karunaratne4, Kailash Malhotra4 and Aileen L. Pangan4, 1Oregon Health & Science University, Portland, OR, 2University of Washington and Swedish Medical Center, Seattle, WA, 3University of Alabama at Birmingham, Birmingham, AL, 4AbbVie Inc., North Chicago, IL

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS) and spondylarthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment III

Session Type: Abstract Submissions (ACR)

Background/Purpose: The age-adjusted prevalence of spondyloarthritis (SpA) has been estimated to be 0.9-1.4% of the US population using the Amor and ESSG criteria. The objective of this study was to determine the prevalence of non-radiographic axial SpA (nr-axSpA) based on the Assessment of Spondyloarthritis International Society (ASAS) axial SpA criteria among undiagnosed patients (pts) with chronic back pain.  

Methods: This is an ongoing, non-drug, multicenter study in the US. Pts previously undiagnosed with SpA, who have had chronic back pain for ≥3 months, with age at onset of <45 years, and at least 1 of the following: 1) positive HLA-B27, 2) current inflammatory back pain, or 3) imaging (MRI or x-ray) evidence of sacroiliitis were included. Pts were either new referrals from other physicians, self-referred, or existing pts in the rheumatologist’s clinic. Medical history, physical exam findings, disease activity measures, and laboratory and imaging test results were collected. The rheumatologist was asked if a diagnosis of axial SpA could be made based on this information and the level of confidence with the diagnosis. Data collected were then analyzed independently to determine which patients are classified as nr-axSpA based on fulfillment of the ASAS criteria for axial SpA, but not modified New York (modNY) criteria for ankylosing spondylitis (AS). 

Results: As of February 2013, 459 pts have been enrolled (31.6% new referrals, 6.5% self-referred, and 61.9% existing pts at the site). 210 (46%) pts fulfilled ASAS criteria, of whom 146 (32%) were classified as nr-axSpA (fulfilled ASAS but not modNY criteria), 59 (13%) classified as AS (fulfilled ASAS and modNY criteria), and 5 (1%) had missing data that did not allow for evaluation of fulfillment of the modNY criteria. Of those who fulfilled ASAS criteria and had available data, 74% were also given a diagnosis of axial SpA by the investigator (95% of those classified as AS and 64% of those classified as nr-axSpA). In addition, 20% of pts who did not fulfill ASAS criteria were given a diagnosis of axial SpA by the investigator, although the overall level of confidence in the diagnosis was lower for these pts. Demographics and disease characteristics for pts classified as nr-axSpA are presented in the Table.

 

Table.  Baseline Demographics and Disease Characteristics of Patients Classified as nr-axSpA*

Characteristic

nr-axSpA

N=146

Gender, n (%)

 

     Female

76 (52.1)

 Age (years)

 

     Mean (SD)

40 (12.3)

Duration of chronic back pain (months)

 

     Mean (SD)

166 (145.7)a

 Age at onset of chronic back pain (years)

 

     Mean (SD)

27 (9.3)a

Human leukocyte antigen-B27 (HLA-B27), n (%)

 

     Positive

 110 (75.3)

Bath AS functional index (BASFI)

 

     Mean (SD)

 4.4 (2.6)

Bath AS disease activity index (BASDAI)

 

     Mean (SD)

 5.9 (2.1)

AS Disease Activity Score (ASDAS)

 

     Mean (SD)

 2.3 (0.8)b

hs-CRP or CRP, category

 

     Elevated

 48 (34.3)b

     Missing

 6

*fulfilled ASAS but not modNY criteria

an=144.  bn=140

Conclusion: Almost half of pts enrolled with chronic back pain and at least 1 SpA-related feature were classified as having axial SpA based on ASAS criteria. Two-thirds of these axial SpA pts had nr-axSpA, with an average of 14 years of symptoms, indicating a substantial delay in diagnosis. The majority of pts who fulfilled ASAS criteria were also diagnosed as having axial SpA by US rheumatologists, but a quarter of these patients were not.


Disclosure:

A. A. Deodhar,

AbbVie, Merck-Sharp-Dohme, Pfizer and UCB,

5,

AbbVie, Merck-Sharp-Dohme, Pfizer and UCB,

8,

AbbVie, Amgen, Novartis, UCB,

2;

P. J. Mease,

AbbVie, Amgen, BiogenIdec, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen Lilly, Merck, Merck-Serono, Novartis, Novo-Nordisk, Pfizer, Roche, UCB, and Vertex,

2,

AbbVie, Amgen, BiogenIdec, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen Lilly, Merck, Merck-Serono, Novartis, Novo-Nordisk, Pfizer, Roche, UCB, and Vertex,

5,

AbbVie, Amgen, BiogenIdec, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen Lilly, Merck, Merck-Serono, Novartis, Novo-Nordisk, Pfizer, Roche, UCB, and Vertex,

8;

J. R. Curtis,

from Janssen, Amgen, Abbvie, UCB, CORRONA, Crescendo, BMS, Roche/Genentech, Pfizer, Celgene, Medimmune,

2,

from Janssen, Amgen, Abbvie, UCB, CORRONA, Crescendo, BMS, Roche/Genentech, Pfizer, Celgene, Medimmune,

5;

P. M. Karunaratne,

AbbVie,

1,

AbbVie,

3;

K. Malhotra,

AbbVie,

1,

AbbVie,

3;

A. L. Pangan,

AbbVie,

1,

AbbVie,

3.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-axial-spondyloarthritis-in-the-united-states-among-patients-with-chronic-back-pain-and-other-spondyloarthritis-related-features/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology